Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study.

Autor: Kemp W; Department of Gastroenterology, The Alfred Hospital, Melbourne, Victoria, Australia.; Central Clinical School, Monash University, Melbourne, Victoria, Australia., Clayton-Chubb D; Department of Gastroenterology, The Alfred Hospital, Melbourne, Victoria, Australia., Majeed A; Department of Gastroenterology, The Alfred Hospital, Melbourne, Victoria, Australia.; Central Clinical School, Monash University, Melbourne, Victoria, Australia., Glenister KM; Department of Rural Health, University of Melbourne, Melbourne, Victoria, Australia., Magliano DJ; Diabetes and Population Health, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia., Lubel J; Department of Gastroenterology, The Alfred Hospital, Melbourne, Victoria, Australia.; Central Clinical School, Monash University, Melbourne, Victoria, Australia., Bourke L; Department of Rural Health, University of Melbourne, Melbourne, Victoria, Australia., Simmons D; Department of Rural Health, University of Melbourne, Melbourne, Victoria, Australia.; Macarthur Clinical School, School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia., Roberts SK; Department of Gastroenterology, The Alfred Hospital, Melbourne, Victoria, Australia.; Central Clinical School, Monash University, Melbourne, Victoria, Australia.
Jazyk: angličtina
Zdroj: Journal of gastroenterology and hepatology [J Gastroenterol Hepatol] 2022 Feb; Vol. 37 (2), pp. 395-403. Date of Electronic Publication: 2021 Nov 04.
DOI: 10.1111/jgh.15723
Abstrakt: Background and Aims: Clinical and public health implications of the recent redefining of non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD) remain unclear. We sought to determine the prevalence and compare MAFLD with NAFLD in a well-defined cohort.
Methods: A cross-sectional study was conducted in regional Victoria with participants from randomly selected households. Demographic and health-related clinical and laboratory data were obtained. Fatty liver was defined as a fatty liver index ≥ 60 with MAFLD defined according to recent international expert consensus.
Results: A total of 722 participants were included. Mean age was 59.3 ± 16 years, and 55.3% were women with a median body mass index of 27.8 kg/m 2 . Most (75.2%) participants were overweight or obese. MAFLD was present in 341 participants giving an unadjusted prevalence of 47.2% compared with a NAFLD prevalence of 38.7%. Fifty-nine (17.5%) participants met the criteria of MAFLD but not NAFLD. The increased prevalence of MAFLD in this cohort was primarily driven by dual etiology of fatty liver. All participants classified as NAFLD met the new definition of MAFLD. Compared with NAFLD subjects, participants with MAFLD had higher ALT (26.0 [14.0] U/L vs 30.0 [23] U/L, P = 0.024), but there were no differences in non-invasive markers for steatosis or fibrosis.
Conclusion: Metabolic-associated fatty liver disease is a highly prevalent condition within this large community cohort. Application of the MAFLD definition increased prevalence of fatty liver disease by including people with dual etiologies of liver disease.
(© 2021 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.)
Databáze: MEDLINE
Externí odkaz: